Comparison of efficacy between beractant and poractant alfa in respiratory distress syndrome among preterm infants (28–33+6 weeks gestational age) using the less invasive surfactant administration (LISA) technique: A randomized controlled trial-Reference-Cited by-同舟云学术

Comparison of efficacy between beractant and poractant alfa in respiratory distress syndrome among preterm infants (28–33+6 weeks gestational age) using the less invasive surfactant administration (LISA) technique: A randomized controlled trial

Published:2024-04-12 Issue: Volume: Page:
ISSN:0743-8346
Container-title:Journal of Perinatology
language:en
Short-container-title:J Perinatol

Author:

Zamal Ashadur^ORCID,Sk Md Habibullah,Saha Bijan^ORCID,Hazra Avijit

Publisher

Springer Science and Business Media LLC

Link

https://www.nature.com/articles/s41372-024-01962-y.pdf

Reference31 articles.

1. Sweet DG, Carnielli VP, Greisen G, Hallman M, Klebermass-Schrehof K, Ozek E, et al. European Consensus Guidelines on the Management of Respiratory Distress Syndrome: 2022 Update. Neonatology. 2023;120:3–23. https://doi.org/10.1159/000528914.

2. Aldana-Aguirre JC, Pinto M, Featherstone RM, Kumar M. Less invasive surfactant administration versus intubation for surfactant delivery in preterm infants with respiratory distress syndrome: a systematic review and meta-analysis. Arch Dis Child Fetal Neonatal Ed. 2017;102:F17–F23. https://doi.org/10.1136/archdischild-2015-310299.

3. Kakkilaya V, Gautham KS. Should less invasive surfactant administration (LISA) become routine practice in US neonatal units? Pediatr Res. 2023;93:1188–98. https://doi.org/10.1038/s41390-022-02265-8.

4. Taylor G, Jackson W, Hornik CP, Koss A, Mantena S, Homsley K, et al. Surfactant administration in preterm infants: drug development opportunities. J Pediatr. 2019;208:163–8.

5. Survanta [package insert] North Chicago, IL: AbbVie, Inc; 2023. https://www.rxabbvie.com/pdf/survanta_pi.pdf Accessed December 17, 2023.